Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) reported on Tuesday the receipt of tentative approval from the US Food and Drug Administration for the first to file generic version of Ultravate Lotion (halobetasol propionate) 0.05%.
The company added that the Ultravate Lotion, 0.05% is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.
In conjunction, the company has announced a patent litigation suit with Sun Pharmaceutical Industries Inc and MiCal Pharmaceuticals LLC for Ultravate Lotion, 0.05%.
For the 12 months ending September 2018, the annual market sales were approximately USD17m as measured by IQVIA, concluded the company.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream